CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Latest Progress, Future Possibilities, and Implications for Patient Care

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer.

Target Audience
This program is intended for nurse practitioners, physician associates, clinical nurse specialists, and advanced degree nurses who manage patients with HR+/HER2- breast cancer. 

Learning Objectives
Upon completion of this activity, participants should be able to:

• Explain the role of risk assessment and biomarkers in guiding optimal therapy selection in patients with HR+/HER2- EBC and MBC
• Create individualized strategies for adjuvant therapy in patients with high-risk, HR+/HER2- EBC, considering tumor characteristics, predictive biomarkers, the latest clinical data, approvals, guidelines, and expert recommendations
• Formulate treatment plans for sequencing therapy in patients with HR+/HER2- MBC based on risk assessment, the latest clinical data, approvals, guidelines, and expert recommendations
• Apply recommended strategies to improve patient recognition of adverse events associated with CDK4/6 inhibitors for high-risk HR+/HER2- breast cancer and to monitor and manage the AEs appropriately
• Initiate discussions with patients to identify and address challenges to adherence and persistence with oral therapies targeting CDK4/6

Agenda:

• Welcome and Introductions
• Fundamentals I: Individualizing Adjuvant Therapy for HR-Positive/HER2-Negative EBC
• Skill Building and Feedback I: Role-Play and Patient Counseling on EBC Assessment and Treatment
• Reflection and Commitment to Practice Change I
• Fundamentals II: Individualizing Therapy for HR-Positive/HER2-Negative MBC
• Skill Building and Feedback II: Role-Play and Patient Counseling on MBC Assessment and Treatment
• Reflection and Commitment to Practice Change II
• Fundamentals III: Addressing AEs and Adherence Challenges
• Skill Building and Feedback III: Role-Play and Patient Counseling on AEs and Adherence
• Reflection and Commitment to Practice Change III
• Final Thoughts and Audience Question and Answer Session